A5101661627- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Inflammatory Bowel Disease
- Microscopic Colitis
- Crystallography and molecular interactions
- Gut microbiota and health
- Clostridium difficile and Clostridium perfringens research
- MicroRNA in disease regulation
- RNA Interference and Gene Delivery
- Fungal Biology and Applications
- Helicobacter pylori-related gastroenterology studies
- Advanced biosensing and bioanalysis techniques
- Autoimmune and Inflammatory Disorders
- Ginseng Biological Effects and Applications
- Epigenetics and DNA Methylation
- Polysaccharides and Plant Cell Walls
- RNA modifications and cancer
- Extracellular vesicles in disease
- Cancer-related molecular mechanisms research
- Pharmacological Effects of Natural Compounds
- Pancreatic and Hepatic Oncology Research
- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Probiotics and Fermented Foods
- Cancer Research and Treatments
Ministry of Agriculture and Rural Affairs
2025
Lanzhou Institute of Husbandry and Pharmaceutical Sciences
2025
Shandong Academy of Sciences
2022-2024
Qilu University of Technology
2022-2024
Shanghai East Hospital
2022-2024
South China University of Technology
2020-2024
Guangzhou Medical University
2020-2024
Guangzhou First People's Hospital
2020-2024
Shanghai Traditional Chinese Medicine Hospital
2024
Shanghai University of Traditional Chinese Medicine
2024
Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis.We conducted two integrated randomized, double-blind, placebo-controlled trials in patients with active disease. In the trial induction therapy, 374 (cohort 1) received (at a dose 300 mg) or placebo intravenously at weeks 0 and 2, 521 2) open-label disease evaluation week 6. maintenance either cohort who had response to 6 were randomly assigned continue receiving every 8...
The efficacy of vedolizumab, an α4β7 integrin antibody, in Crohn's disease is unknown.In integrated study with separate induction and maintenance trials, we assessed intravenous vedolizumab therapy (300 mg) adults active disease. In the trial, 368 patients were randomly assigned to receive or placebo at weeks 0 2 (cohort 1), 747 received open-label 2); status was week 6. 461 who had a response every 8 4 until 52.At 6, total 14.5% cohort 1 6.8% clinical remission (i.e., score on Disease...
Background & AimsThere is an increasing need for new treatments patients with Crohn's disease (CD) in whom previous therapy tumor necrosis factor (TNF) antagonists has failed. We performed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety of vedolizumab, antibody against integrin α4β7, as induction therapy.MethodsPatients moderately severely active CD (CD activity index [CDAI] score, 220–400 points) were assigned randomly groups given vedolizumab (300 mg)...
Plant-derived exosome-like nanoparticles (PDENs) have been paid great attention in the treatment of ulcerative colitis (UC). As a proof concept, we isolated and identified Portulaca oleracea L-derived (PELNs) from edible L, which exhibited desirable nano-size (~ 160 nm) negative zeta potential value (-31.4 mV). Oral administration PELNs effectively suppressed expressions pro-inflammatory cytokines (TNF-α, IL-6, IL-12, IL-1β) myeloperoxidase (MPO), increased levels anti-inflammatory cytokine...
Extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) pretreated with atorvastatin (ATV) (MSC
BackgroundVedolizumab is a gut-selective α4β7 integrin antagonist for the treatment of moderately to severely active Crohn's disease (CD). Aims this study were characterize efficacy and safety vedolizumab induction maintenance therapy in patients who naïve tumor necrosis factor-alpha (TNF-α) (TNF-naïve) or had discontinued TNF-α because inadequate response (i.e., primary nonresponse), loss response, intolerance (collectively classified as TNF-failure population).
Medical management of fistulising Crohn's disease [CD] is constrained by the limited number available therapies. We evaluated efficacy vedolizumab, a gut-selective α4β7 integrin antagonist approved for treating moderately to severely active CD, in subpopulation patients with CD who participated GEMINI 2 trial [NCT00783692].Exploratory analyses data from were conducted 461 responders 6-week vedolizumab induction therapy received maintenance placebo [VDZ/PBO, N = 153] or [VDZ/VDZ, 308]....
Abstract Background Dextran sulfate sodium (DSS) replicates ulcerative colitis (UC)-like in murine models. However, the microbial characteristics of DSS-triggered require further clarification. To analyze changes gut microbiota associated with DSS-induced acute and chronic colitis. Methods Acute was induced mice by administering 3% DSS for 1 week drinking water, supplementing water 2.5% every other 5 weeks. Control groups received same without supplementation. The histopathological score...
Abstract An increasing number of studies have shown that Faecalibacterium prausnitzii ( F. ) is a promising anti-inflammatory bacterium colonizes in the gut and microbiota dysbiosis plays an important role pathogenesis inflammatory bowel disease (IBD). In this study, we report profile 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis mice treated with its supernatant on basis high-throughput sequencing. We interestingly found both metabolites exerted protective effects against mice,...
Abstract Background Bone marrow cells (BMCs), especially mesenchymal stem (MSCs), have shown attractive application prospects in acute myocardial infarction (AMI). However, the weak efficacy becomes their main limitation clinical translation. Based on anti-inflammation and anti-apoptosis effects of a Chinese medicine-Tongxinluo (TXL), we aimed to explore TXL-pretreated MSCs (MSCs TXL ) enhancing cardiac repair further investigated underlying mechanism. Methods or derived exosomes -exo...
Abstract Background Patients with inflammatory bowel disease (IBD), dysbiosis, and immunosuppression who receive fecal microbiota transplantation (FMT) from healthy donors are at an increased risk of developing bacteremia. This study investigates the efficacy a mixture seven short-chain fatty acid (SCFA)-producing bacterial strains (7-mix), resulting culture supernatant (mix-sup), FMT for treating experimental ulcerative colitis (UC) evaluates underlying mechanisms. Methods Utilizing...
BackgroundVedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has shown preliminary efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We report long-term experience with vedolizumab for active UC CD.
The objective of this study was to evaluate qualitative and quantitative biodistribution epidermal growth factor receptor (EGFR)-targeted thiolated type B gelatin nanoparticles in vivo subcutaneous human pancreatic adenocarcinoma (Panc-1) bearing female SCID Beige mice. EGFR-targeted showed preferential sustained accumulation the tumor mass, especially at early time points. Higher blood concentrations higher accumulations were observed with PEG-modified during (AUClast: 17.38 19.56%ID/mL·h...
Fecal microbiota transplantation (FMT) can inhibit the progression of ulcerative colitis (UC). However, how FMT modulates gut and which biomarker is valuable for evaluating efficacy have not been clarified. This study aimed to determine changes in their relationship with butyric acid following UC. (FM) was isolated from healthy individuals or mice transplanted into 12 UC patients induced by dextran sulfate sodium (DSS). Their clinical severities were monitored. analyzed 16S sequencing...
Ganoderma lucidum is known as a medicine food homology that can ameliorate gastrointestinal diseases. To evaluate the gastroprotective effects on different polysaccharides (GLPs), GLP was separated into three parts with molecular weights using 100 kDa, 10 and 1 kDa membranes. The mitigation of GLPs ethanol-induced acute gastric injury were observed in rats. After pretreatment GLPs, especially above symptoms mucosal congestion bleeding improved; serum myeloperoxidase, inflammatory factor,...
Pancreatic adenocarcinoma is one of the most dreaded cancers with very low survival rate and poor prognosis to existing frontline chemotherapeutic drugs. Gene therapy in combination a cytotoxic agent could be promising approach circumvent limitations previously attempted therapeutic interventions. We have developed redox-responsive thiolated gelatin based nanoparticle system that efficiently delivers its payload presence glutathione-mediated reducing intra-cellular environment successfully...